The financials
BeOne Medicines AG by the numbers
Its largest product in 2026-Q2 was BRUKINSA at $1.25B, 72% of the disclosed total, just ahead of TEVIMBRA at 13%.
| Product | Revenue | Share |
|---|---|---|
| BRUKINSA | $1.25B | 72% |
| TEVIMBRA | $229M | 13% |
| XGEVA | $104M | 6.0% |
| Other | $38M | 2.2% |
| BLINCYTO | $37M | 2.1% |
| Other | $25M | 1.5% |
| Amgen Royalty | $19M | 1.1% |
| KYPROLIS | $15M | 0.9% |
| POBEVCY | $9.6M | 0.6% |
| Novartis Broad Markets | $5.0M | 0.3% |
| Collaboration Other | $1.5M | 0.1% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $1.73B (+3214%)
Amgen Royalty grew +108% year on yearKYPROLIS -22% year on year
Segment Latestquarter on quarteryear on year
- BRUKINSA$1.25B$1.25BQoQ -year on year +31%-+31%
- TEVIMBRA$228.5M$228.5MQoQ -year on year +18%-+18%
- XGEVA$104.5M$104.5MQoQ -year on year +29%-+29%
- Other$37.8M$37.8MQoQ -year on year +79%-+79%
- BLINCYTO$36.5M$36.5MQoQ -year on year +43%-+43%
- Other$25.3M$25.3MQoQ -3.2%year on year +91%-3.2%+91%
- Amgen Royalty$18.8M$18.8MQoQ +2.9%year on year +108%+2.9%+108%
- KYPROLIS$15.1M$15.1MQoQ -year on year -22%--22%
- POBEVCY$9.6M$9.6MQoQ -year on year -14%--14%
- Novartis Broad Markets$5.0M$5.0MQoQ -5.8%year on year +49%-5.8%+49%
- Collaboration Other$1.5M$1.5MQoQ -41%year on year +72%-41%+72%
- Collaboration--QoQ -year on year ---
Biotechnology
Ranks #58 of 145 by Smart Score